Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28 2022 - 4:05PM
Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ:
OPNT), a specialty pharmaceutical company developing medicines to
treat addictions and drug overdose, today announced the
Compensation and Human Capital Committee of the Company’s Board of
Directors has approved the grant of restricted stock units (“RSU”)
covering an aggregate of 25,900 shares of common stock to seven
hired employees, pursuant to the Company’s 2022 Inducement Equity
Incentive Plan (“Inducement Plan”). The RSUs were granted as
material inducements to employment in accordance with Nasdaq
Listing Rule 5635(c)(4).
Each RSU will vest over a four-year period, with 25% of the
shares vesting on the one-year anniversary of the date of grant,
and thereafter an additional 25% of the shares vesting on each
succeeding one-year anniversary of the date of grant, subject to
such employee’s continued employment with Opiant on such vesting
dates. Each RSU is subject to the terms and conditions of the
Inducement Plan and the terms and conditions of an RSU agreement
covering the grant.
About Opiant Pharmaceuticals,
Inc. Opiant Pharmaceuticals, Inc., the company that
developed NARCAN® Nasal Spray, is building a
leading franchise of new medicines to combat addictions
and drug overdose. For more information
visit: www.opiant.com.
Forward-Looking StatementsThis press release
contains forward-looking statements. These statements relate to
future events or our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause
our actual results, levels of activity, performance or achievements
to be materially different from any future results, levels of
activity, performance or achievements expressed, implied or
inferred by these forward-looking statements, and among other
things, completion of the NDA filing in the second half of 2022. In
some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "could," "would,"
"expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "projects," "potential," or "continue" or
the negative of such terms and other comparable terminology. These
statements are only predictions based on our current expectations
and projections about future events. You should not place undue
reliance on these statements. Actual events or results may differ
materially. In evaluating these statements, you should specifically
consider various factors. Additional factors that could materially
affect actual results can be found in our Form 10-K for the year
ended December 31, 2021 and our Form 10-Q for the quarter
ended March 31,2022, filed with the Securities and Exchange
Commission on March 4, 2022 and May 10, 2022,
respectively, including under the caption titled "Risk Factors."
These and other factors may cause our actual results to
differ materially from any forward-looking statement. We undertake
no obligation to update any of the forward-looking statements after
the date of this press release to conform those statements to
reflect the occurrence of unanticipated events, except as required
by applicable law.
For Media and Investor Inquiries:Ben Atkins, Opiant(310)
598-5410batkins@opiant.com
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Sep 2023 to Sep 2024